Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

GSK, INNOVAX and Xiamen University to jointly develop cervical cancer vaccine

Xinhua | Updated: 2019-09-07 14:26
Share
Share - WeChat
The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai. [Photo/Agencies]

BRUSSELS - INNOVAX, a subsidiary of China's YangShengTang Group, and Xiamen University signed a global alliance partnership agreement on Friday with British pharmaceutical giant GlaxoSmithKline (GSK) in Wavre, Belgium, to develop a next-generation vaccine against human papillomavirus (HPV).

Zhong Shanshan, chairman of YangShengTang Group, announced this in an interview with Xinhua.

This vaccine will combine the innovative antigen detection method developed by Prof Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.

Shazia Sheikh, director of public affairs for global and emerging markets at GSK Vaccine, confirmed the news via email on Friday.

Zhong stressed that this is the first time a Chinese vaccine company, by leveraging its original technology, has entered into a partnership with a world leading vaccine company to co-develop and ultimately commercialize an important vaccine globally. This alliance shows that China's vaccine technology has been highly regarded by its international counterparts. And the partnership is an exemplary collaboration between the pharmaceutical industries of China and Europe.

Zhang Rong, president of Xiamen University, told Xinhua that biological research at Xiamen University has a history of nearly one hundred years. Making scientific and technological achievements that are beneficial to human health and wellbeing and promoting their commercialization is consistent with the University's mission.

"This partnership is a milestone in the past 20 years of industry-research collaboration between INNOVAX and Xiamen University. It is also a commercial cooperation between a Chinese vaccine company and a global vaccine company from Europe. But, above all, it is a model of how the international academic and industrial community can join hands to fight human diseases," he added.

Under the agreement, INNOVAX will build a vaccine production line in Xiamen, Southeast China, that will comply with the standards set by China, the United States, the European Union and the World Health Organization. It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK's patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

GSK said the partnership with INNOVAX will accelerate the development of the next generation of its cervical cancer vaccine.

According to Zhong, the antigen technology was born in the joint biopharmaceuticals laboratory of Xiamen University and YangShengTang led by Professor Xia. It successfully used DNA recombination technology to express proteins in E coli and used it for vaccine production. INNOVAX's cervical cancer vaccine is highly effective in that it protects more HPV types with fewer virus-like particles (VLPs).

The bivalent cervical cancer vaccine co-developed by INNOVAX and Prof. Xia's team is the first Chinese cervical cancer vaccine that has completed the Phase III clinical trial. Commercialization of this vaccine will make China the world's third country with the ability to independently manufacture cervical cancer vaccines after the US and the UK. GSK accelerated partnership talks between the two parties in November, 2018, when INNOVAX's Phase III clinical trial data on cervical cancer vaccine were released.

The cervical cancer vaccine has broad market prospects globally. Cervical cancer is the third most common cancer in women. It is estimated that every year 311,365 women are killed and in every two minutes, a woman will die of cervical cancer. Almost all cases of cervical cancer are caused by the human papillomavirus (HPV). Over 100 types of HPV virus are known, and over 15 of them can cause cervical cancer.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产精品视频免费播放| 日韩爽爽视频爽爽| 国产av无码久久精品| 香蕉网站在线观看| 小娇乳H边走边欢1V1视频国产| 乱色熟女综合一区二区三区| 特级毛片在线大全免费播放| 国产乱女乱子视频在线播放| 香焦视频在线观看黄| 夭天曰天天躁天天摸在线观看 | 亚洲Aⅴ在线无码播放毛片一线天| 看国产一级毛片| 国产亚洲av手机在线观看| 男女一边摸一边爽爽视频| 奇米影视第四色在线| 久久99国产乱子伦精品免费| 欧美三级中文字幕在线观看| 人善交另类欧美重口另类| 老色鬼久久综合第一| 国产成人精品午夜福利| 5g影院天天爽天天| 奇米小说首页图片区小说区| 中文字幕在线一区二区三区| 日韩成全视频观看免费观看高清| 亚洲国产综合精品| 特级av毛片免费观看| 午夜体验试看120秒| 被男按摩师添的好爽在线直播 | 欧美丝袜一区二区三区| 亚洲视频免费在线观看| 绿巨人草莓香蕉丝瓜菠萝| 国产伦精品一区二区三区免.费| 亚洲成a人片在线看| 国产黄色大片网站| www.亚洲日本| 成人H动漫精品一区二区| 久久久www成人免费精品| 日韩精品久久久久久| 亚洲啪啪综合AV一区| 欧美野性肉体狂欢大派对| 免费a级毛视频|